- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07652788
Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD) (TDACS)
Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD): A Randomized Double-Blind Controlled Trial
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by attentional difficulties and/or hyperactivity-impulsivity (American Psychiatric Association, 2013). Its treatment is primarily based on a multimodal approach, with first-line pharmacological management using methylphenidate (Ritalin®, Medikinet®, etc.).
However, given the limitations of pharmacological treatments (side effects, contraindications, and risks of misuse), alternative approaches such as transcranial direct current stimulation (tDCS) are generating increasing interest.
tDCS is a non-invasive, safe, and low-cost neuromodulation technique that delivers a low-intensity electrical current through electrodes placed on the scalp. It is well tolerated, with mild and transient adverse effects (tingling sensations, local skin redness, mild fatigue), making it a particularly safe approach. Its low cost and ease of use allow for broad accessibility, including in resource-limited healthcare settings.
In ADHD, tDCS targets the left dorsolateral prefrontal cortex, a key region involved in attention and executive functions. Early studies have reported encouraging results in terms of both efficacy and tolerability, particularly when combined with psychotherapeutic interventions.
The aim of this study is to evaluate the efficacy of tDCS in patients with ADHD.
The findings will support the potential future integration of tDCS into the management of ADHD resistant to conventional treatments.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Adult patient aged 18 to 60 years inclusive
- Patient diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD), combined or predominantly inattentive presentation, previously established by a healthcare professional
- Patients must be registered in the active caseload of the Adult Neurodevelopmental Disorders Unit (STNDA)
- Stable psychotropic medication regimen for at least four weeks prior to inclusion, in terms of both molecule and dosage, particularly for methylphenidate, or no current psychotropic treatment. Medication must remain unchanged throughout study participation, unless medically justified changes are required
- Patient with a cognitive status deemed sufficient by the unit's referring psychiatrist to ensure appropriate completion of the scales and tests included in the protocol
- Free, informed, and written consent
Exclusion Criteria:
•General condition impairment (severe fatigue or marked weakness, convalescence after an acute illness or surgery, or recent alcohol consumption)
Psychiatric and neurological disorders
- Diagnosis of Autism Spectrum Disorder (ASD)
- Diagnosis of personality disorder (Cluster A, B, C, or other), according to DSM-5-TR
- Diagnosis of schizophrenia spectrum disorder or other psychotic disorders according to DSM-5-TR
- Diagnosis of bipolar disorder with manic episode or history of manic episodes according to DSM-5-TR
- Confirmed neurological disorder
- Epilepsy or history of epileptic seizures
Medical comorbidities
- Patient with known or suspected cardiac disease
- Patient with severe pulmonary disease
- Patient with cerebrovascular disease (e.g., stroke)
Dermatological and surgical contraindications
- Patient with scalp lesions, open wounds, or skin conditions (severe acne, herpes, burns, skin fissures)
- Patient with severe dermatitis, oozing eczema, or fragile scalp
- Patient with major surgical scars
- Patient with recent craniotomy
Implantable devices and materials
• Patient with a pacemaker or intracranial electrodes, presence of intracranial metal, or skull defects (e.g., post-craniectomy or trepanation without reconstruction)
Other criteria:
- Simultaneous participation in another non-pharmacological intervention provided in the STNDA day hospital (e.g., psychoeducation, cognitive remediation, body expression therapy, emotional regulation training)
- Patient with non-pathological ASRS screening scores (fewer than 4 of the first 6 items rated "Very often")
- Insufficient proficiency in the French language
- Patient under legal guardianship, curatorship, or judicial protection
- Pregnant or breastfeeding patient (based on clinical interview)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Schein-Komparator: tDCS sham
The placebo (sham) treatment will follow an identical protocol in terms of session duration, frequency, and overall procedure.
Stimulation will be simulated, with a brief ramp-up and ramp-down of current at the beginning and end of the session, without actual stimulation during the remainder of the session, in order to mimic the initial sensations of active tDCS.
|
Repeated sessions of transcranial direct current stimulation (tDCS): 5 in-person tDCS sessions Intensity: 2.0 mA Duration: 20 minutes per session Frequency: 5 consecutive days Electrode placement: anode at F3 and cathode at F4 |
|
Experimental: tactive tDCS
Active transcranial direct current stimulation (tDCS): 2 mA stimulation for 20 minutes. Repeated sessions of transcranial direct current stimulation (tDCS): 5 in-person tDCS sessions Intensity: 2.0 mA Duration: 20 minutes per session Frequency: 5 consecutive days Electrode placement: anode at F3 and cathode at F4 |
Repeated sessions of transcranial direct current stimulation (tDCS): 5 in-person tDCS sessions Intensity: 2.0 mA Duration: 20 minutes per session Frequency: 5 consecutive days Electrode placement: anode at F3 and cathode at F4 |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Inattention Symptoms Assessed by the Adult ADHD Self-Report Scale (ASRS) from Baseline to Immediately After tDCS
Zeitfenster: Baseline and immediately after the last tDCS session
|
The efficacy of tDCS will be assessed by measuring the change in inattention symptoms using the Adult ADHD Self-Report Scale (ASRS).
The ASRS is a self-report questionnaire used to evaluate ADHD symptoms in adults.
A decrease in the ASRS inattention score indicates an improvement in inattention symptoms.
|
Baseline and immediately after the last tDCS session
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Processing Speed Assessed by the WAIS-IV Coding and Symbol Search Subtests
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
Processing speed will be assessed using the Coding and Symbol Search subtests of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV).
Changes in scores will be compared between the active tDCS group and the sham tDCS group.
|
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
|
Change in Working Memory Assessed by the WAIS-IV Digit Span Subtest
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
Working memory will be assessed using the Digit Span subtest of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV).
Changes in scores will be compared between the active tDCS group and the sham tDCS group.
|
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
|
Change in Selective Attention Assessed by the d2-R Test of Attention
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
Selective attention will be assessed using the d2-R Test of Attention.
Changes in attention performance scores will be compared between the active tDCS group and the sham tDCS group.
|
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
|
Change in Emotional Regulation Assessed by the Difficulties in Emotion Regulation Scale - French Version (DERS-F)
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
Emotional regulation will be assessed using the Difficulties in Emotion Regulation Scale - French Version (DERS-F).
Changes in emotional regulation scores will be compared between the active tDCS group and the sham tDCS group.
|
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
|
Change in Anxiety and Depression Symptoms Assessed by the Hospital Anxiety and Depression Scale (HADS)
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
Anxiety and depression symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS).
Changes in anxiety and depression scores will be compared between the active tDCS group and the sham tDCS group.
|
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
|
|
Incidence of Adverse Events Related to tDCS
Zeitfenster: From the first tDCS session through 6 weeks after the last tDCS session
|
The safety and tolerability of tDCS will be assessed by comparing the frequency and nature of adverse events reported in the active tDCS group and the sham tDCS group.
|
From the first tDCS session through 6 weeks after the last tDCS session
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Psychische Störungen
- Neuroentwicklungsstörungen
- Aufmerksamkeitsdefizit und störende Verhaltensstörungen
- Aufmerksamkeitsdefizitstörung mit Hyperaktivität
- Therapeutika
- Verhaltensdisziplinen und Aktivitäten
- Elektrische Stimulationstherapie
- Krampfhafte Therapie
- Psychiatrische somatische Therapien
- Elektroschock
- Psychologische Techniken
- Transkranielle Direktstromstimulation
Andere Studien-ID-Nummern
- 2025-A02038-41
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Transcranial direct current stimulation (tDCS)
-
Florida State UniversityNational Institute of Mental Health (NIMH)RekrutierungAnhedonie | DepressionVereinigte Staaten
-
University of Bernki:elementsRekrutierungAltern | Gesunder Freiwilliger | Depressive Störung, schwere depressive StörungSchweiz
-
National Cheng-Kung University HospitalRekrutierungIschämischer SchlaganfallTaiwan
-
Women's College HospitalUniversity Health Network, Toronto; AFP Innovation FundNoch keine RekrutierungSchmerzen, postoperativ | Knieendoprothetik | Transkranielle GleichstromstimulationKanada
-
Xuanwu Hospital, BeijingRekrutierungRefraktärer Status EpilepticusChina
-
Tianjin Anding HospitalChinese Academy of SciencesAnmeldung auf EinladungSchizophrenie vom negativen TypChina
-
Tianjin Eye HospitalRekrutierung
-
Poznan University of Physical EducationRekrutierungStreicheln | Erkrankungen des Rückenmarks | Endometriose | Dyspareunie | Polyzystischer Eierstock | Nervenwurzelstörung | Schmerzhafte MenstruationPolen
-
Universidade Federal de PernambucoAbgeschlossenTranskranielle Gleichstromstimulation | Stimm- und Resonanzstörungen | StimmstörungBrasilien
-
Tufts UniversityZurückgezogen